PharmaJet® today announced that its partner, Scancell, reported positive results from their Phase 1 COVIDITY clinical trial. The trial was conducted at the University of Cape Town Lung Institute in South Africa to assess the safety and immunogenicity of their COVID-19 DNA candidate vaccines, SCOV1 and SCOV2.
The results from the trial were highly encouraging, inducing neutralizing antibody and T cell responses with no safety concerns. Administration with PharmaJet's devices was well received by study participants.
This new set of human data adds to the growing evidence indicating that this modern needle-free administration technology is an increasingly viable option to enhance plasmid DNA vaccine immune response.
The vaccines were exclusively administered using the PharmaJet Tropis® and Stratis® needle-free precision delivery systems.
Professor Lindy Durrant, Chief Executive Officer, Scancell, commented in a press release on March 21, 2023, "We are encouraged by these results."
"The trial validates that AvidiMab®-modified immunotherapies boost immune responses and PharmaJet's Needle-free Injection Systems are effective in delivering our ImmunoBody®-generated drug candidate."
"Our plans are to include PharmaJet Needle-free precision delivery systems in future trials with our immuno-oncology projects."
PharmaJet Needle-free precision delivery Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to commercialization.
The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.
The Tropis® System has CE Mark and WHO PQS certification for intradermal injections.
They are both commercially available for global immunization programs.
Note: This news article is not paid content.